Gene Variant Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Gene MLH1
Variant negative
Impact List unknown
Protein Effect loss of function
Gene Variant Descriptions MLH1 negative indicates a lack of expression of the MLH1 mRNA and/or protein.
Associated Drug Resistance
Category Variants Paths

MLH1 mutant MLH1 inact mut MLH1 negative

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

No Variant Reference Transcript is Available.
No transcript is Available.

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT03506997 Phase II Pembrolizumab Trial of Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (PERSEUS1) Recruiting GBR 0
NCT05733611 Phase II Atezolizumab + Bevacizumab + RP2 Atezolizumab + Bevacizumab + RP3 RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC Active, not recruiting USA 0
NCT05328908 Phase III Regorafenib + Trifluridine-tipiracil hydrochloride Nivolumab and relatlimab-rmbw A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer (RELATIVITY-123) Active, not recruiting USA | NLD | ITA | FRA | ESP | DEU | CAN | BEL | AUT | AUS 12
NCT06362369 Phase Ib/II 7HP349 + Ipilimumab + Nivolumab A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy Not yet recruiting 0
NCT05843188 Phase II Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Hydroxychloroquine + Irinotecan + Leucovorin Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer Recruiting CAN 0
NCT04272034 Phase I INCB099318 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors Active, not recruiting USA | GBR | BEL 4
NCT04854434 Phase II Trifluridine-tipiracil hydrochloride Pembrolizumab + Selinexor Selinexor A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations Terminated USA 0
NCT05597839 Phase Ib/II DF9001 DF9001 + Nivolumab Study of DF9001 in Patients With Advanced Solid Tumors Recruiting USA 0
NCT04751370 Phase II Ipilimumab + Nivolumab Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer Suspended USA 0
NCT06004245 Phase I RO7589831 A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of RO7589831 in Participants With Advanced Solid Tumors Recruiting USA | GBR | ESP | CAN | BEL 1
NCT04964375 Phase I ABSK043 A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK043 in Patients With Advanced Solid Tumor Unknown status AUS 0
NCT05838768 Phase I HRO761 HRO761 + Tislelizumab HRO761 + Irinotecan Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency. Recruiting USA | FRA | ESP | DEU | BEL 5
NCT04717154 Phase II Ipilimumab + Nivolumab Ipilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate Cancer (INSPIRE) Active, not recruiting NLD 0
NCT03724071 Phase Ib/II Flucytosine + TG6002 Study of TG6002 (VV TK-RR-FCU1) in Combination With 5-FC in Patients With Advanced Gastro-intestinal Tumors. Terminated FRA | ESP | BEL 0
NCT05836584 Phase II Atezolizumab + Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab + Docetaxel + Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab Atezolizumab + Capecitabine + Oxaliplatin Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer Recruiting USA 0
NCT03809624 Phase II INBRX-105 INBRX-105 + Pembrolizumab Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer (PDL1x41BB) Recruiting USA 0
NCT05909995 Phase I INCB099280 + Ipilimumab Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors Recruiting USA | CAN | AUS 5
NCT04393454 Phase II Sirolimus Study to Evaluate the Efficacy and Safety of Sirolimus in Subjects With Metastatic, Mismatch Repair Deficient Solid Tumors After Immunotherapy Terminated USA 0
NCT05592626 Phase Ib/II STAR0602 A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors (START-001) Recruiting USA | CAN 0
NCT06059495 Phase II Dostarlimab-gxly Watch-and-Wait Approach With Dostarlimab in Localized dMMR/MSI-H Gastric Cancer: GERCOR Phase II Study (DEWI) Recruiting FRA 0
NCT05999812 Phase II Atezolizumab + Bevacizumab + Tretinoin Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer Recruiting USA 0
NCT04963283 Phase II Cabozantinib + Nivolumab Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer Active, not recruiting USA 0
NCT06106308 Phase II Fluorouracil + Irinotecan + Leucovorin + Onvansertib Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Onvansertib Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation Recruiting USA 0
NCT04197219 Phase II Axitinib + Pembrolizumab Pembrolizumab With Axitinib in Recurrent Endometrial Cancer Withdrawn 0
NCT05099549 Phase Ib/II AFM24 + SNK01 Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers Terminated USA 0
NCT06180733 Phase II Pembrolizumab Neo-adjuvant Pembrolizumab as an Alternative Treatment for MMRd Uterine Cancer (PAM-II) Recruiting NLD 0
NCT06365970 Phase II Dostarlimab-gxly + Niraparib Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers Not yet recruiting USA 0
NCT04795661 Phase II Pembrolizumab Immunotherapy in MSI/dMMR Tumors in Perioperative Setting. (IMHOTEP) Active, not recruiting FRA 0
NCT05064059 Phase III Regorafenib + Trifluridine-tipiracil hydrochloride MK-4280A A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 13
NCT05382741 Phase II Durvalumab + Regorafenib Adjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial (VIVA) Recruiting ITA 0
NCT05672316 Phase Ib/II Balstilimab + Botensilimab + Regorafenib Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy Recruiting USA 0
NCT05961709 Phase II Cemiplimab The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer Not yet recruiting USA 0
NCT06225843 Phase II AB-16B5 + Fluorouracil + Leucovorin + Oxaliplatin Sotevtamab (AB-16B5) Combined With FOLFOX as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasis (EGIA-003) Recruiting CAN 0
NCT05001516 Phase Ib/II TPX-4589 Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors Completed USA 0
NCT05178576 Phase II XOMA 052 A Single Arm Phase II Study to Evaluate Treatment With Gevokizumab in Patients With Stage II/III Colon Cancer Who Are ctDNA-positive After Curative Surgery and Adjuvant Chemotherapy Withdrawn USA 0
NCT05086692 Phase Ib/II MDNA11 + Pembrolizumab A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1) Recruiting USA | CAN | AUS 1
NCT04019964 Phase II Nivolumab Nivolumab in Biochemically Recurrent dMMR Prostate Cancer Recruiting USA 0
NCT05480306 Phase II Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin DKN-01 + Fluorouracil + Irinotecan + Leucovorin Fluorouracil + Irinotecan + Leucovorin Phase 2 Study of DKN-01 in Colorectal Cancer (DeFianCe) Recruiting USA | DEU 1
NCT05879822 Phase II INCB099280 A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive Recruiting NZL 9
NCT05904496 Phase I BGB-30813 BGB-30813 + Tislelizumab A Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-30813 Recruiting USA | ESP | AUS 0
NCT05032040 Phase II XmAb20717 A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies Recruiting USA 0
NCT05584670 Phase Ib/II SAR445877 A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors Recruiting USA | NLD | ESP 1
NCT05197322 Phase II Pembrolizumab NEOadjuvant PembRolizumab In Stratified Medicine - ColoRectal Cancer (NEOPRISM-CRC) Recruiting GBR 0
NCT06279130 Phase II Balstilimab Balstilimab + Botensilimab Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations (NEOASIS) Recruiting NLD 0
NCT05691491 Phase Ib/II M1774 + Temozolomide Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness Recruiting USA 0
NCT04659382 Phase II Atezolizumab + Bevacizumab + Capecitabine + Oxaliplatin Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer (SIRTCI) Recruiting FRA 0
NCT02675946 Phase I CGX1321 CGX1321 + Pembrolizumab Cetuximab + CGX1321 + Encorafenib CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596) Unknown status USA 1
NCT04976634 Phase II Belzutifan + Lenvatinib + Pembrolizumab Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016) Recruiting USA | NZL | NLD | FRA | ESP | BEL | AUS 3
NCT06346197 Phase III Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin Capecitabine + Nivolumab + Oxaliplatin Balstilimab + Botensilimab Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas (CIME) Not yet recruiting FRA 0
NCT05615818 Phase III Niraparib ZW25 Binimetinib + Encorafenib Futibatinib Cisplatin + Gemcitabine Neratinib + Trastuzumab Ivosidenib Personalized Medicine for Advanced Biliary Cancer Patients (SAFIR-ABC10) Not yet recruiting GBR | FRA | BEL 0
NCT06006923 Phase II Pembrolizumab Pembrolizumab + Regorafenib Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer Not yet recruiting USA 0
NCT03519412 Phase II Pembrolizumab Temozolomide Pembrolizumab + Temozolomide Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation Status (ARETHUSA) Active, not recruiting ITA 0
NCT04984733 Phase II Nivolumab + Temozolomide Temozolomide + Nivolumab in MGMT Methylated Oesophagogastric Cancer (ELEVATE) Recruiting GBR 0
NCT03851614 Phase II Cediranib + Durvalumab Durvalumab + Olaparib Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors (DAPPER) Active, not recruiting CAN 0
NCT04166721 Phase Ib/II Atezolizumab + DKN-01 WaKING: Wnt and checKpoint INhibition in Gastric Cancer Recruiting GBR 0
NCT06205836 Phase II Cemiplimab Cemiplimab + Fianlimab Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer Not yet recruiting USA 0
NCT05173987 Phase III Cisplatin + Docetaxel Carboplatin + Docetaxel Carboplatin + Paclitaxel Cisplatin + Paclitaxel Pembrolizumab Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15) Active, not recruiting USA | NZL | NLD | ITA | GBR | ESP | DEU | CAN | BEL | AUS 17
NCT05167409 Phase II Cetuximab + Evorpacept + Pembrolizumab A Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer Active, not recruiting USA 0
NCT05608044 Phase II Balstilimab + Botensilimab Botensilimab A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer Active, not recruiting USA | ITA | FRA | ESP | BEL 2
NCT05310643 Phase II Ipilimumab + Nivolumab Nivolumab and Ipilimumab in Patients With dMMR and/or MSI Metastatic Colorectal Cancer Resistant to Anti-PD1 Monotherapy (NIPIRESCUE) Recruiting FRA 0
NCT06056323 Phase Ib/II HB0045 A Study of HB0045 Injection in Patients With Advanced Solid Tumors Recruiting USA 0
NCT05609370 Phase Ib/II Bevacizumab + Capecitabine Bevacizumab + Fluorouracil + LBL-007 + Tislelizumab Bevacizumab + Fluorouracil + LBL-007 Bevacizumab + Fluorouracil Bevacizumab + Capecitabine + LBL-007 + Tislelizumab Bevacizumab + Capecitabine + LBL-007 A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer Recruiting USA | AUS 2
NCT05784688 Phase Ib/II Pembrolizumab + TU2218 Study of TU2218 in Combination With Pembrolizumab in Patients With Advanced Solid Tumors Recruiting USA 0
NCT05156268 Phase II Olaparib + Pembrolizumab A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma Recruiting USA 0
NCT03475953 Phase Ib/II Avelumab + Regorafenib A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (REGOMUNE) Recruiting FRA 0
NCT05141721 Phase II Atezolizumab + GRT-C901 + GRT-R902 + Ipilimumab A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer Active, not recruiting USA 0
NCT02998567 Phase I Guadecitabine + Pembrolizumab Decitabine and Cedazuridine + Pembrolizumab Combination Study of Guadecitabine/ASTX727 and Pembrolizumab (HyPeR) Recruiting GBR 0
NCT06300463 Phase II Balstilimab + Botensilimab + GS-1423 Balstilimab + Botensilimab Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases Recruiting USA 0
NCT04800627 Phase Ib/II MLN4924 + Pembrolizumab Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally Advanced Unresectable Solid Tumor Terminated USA 0
NCT05593328 Phase II Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Onvansertib Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation Active, not recruiting USA 0
NCT05322590 Phase Ib/II BXQ-350 BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma (ASIST) Recruiting USA 0
NCT05722886 Phase II Cobimetinib + Vemurafenib Alectinib Pertuzumab + Trastuzumab Entrectinib Atezolizumab DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol (DETERMINE) Recruiting GBR 0
NCT05205330 Phase Ib/II Balstilimab + CR6086 A Phase Ib/IIa Study of CR6086 in Combination With Balstilimab in pMMR-MSS Metastatic Colorectal Cancer Patients Active, not recruiting ITA 0
NCT04262687 Phase II Bevacizumab + Capecitabine + Oxaliplatin + Pembrolizumab Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate (POCHI) Recruiting FRA 0
NCT05337735 Phase II XmAb20717 A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers Recruiting USA 0
NCT04730544 Phase II Ipilimumab + Nivolumab Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC. (NIPISAFE) Recruiting FRA 0
NCT05510895 Phase II Binimetinib + Cetuximab + Encorafenib Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer (NeoBRAF) Recruiting DEU 0
NCT05330429 Phase II Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Hu5F9-G4 + Irinotecan + Leucovorin Study of Magrolimab Given Together With FOLFIRI/BEV in Patients With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC) (ELEVATE CRC) Active, not recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL | AUS 2
NCT05902988 Phase Ib/II VLS-1488 A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer Recruiting USA 0
NCT06047379 Phase Ib/II NEO212 NEO212 + Regorafenib Carboplatin + NEO212 + Paclitaxel Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + NEO212 Ipilimumab + NEO212 NEO212 + Pembrolizumab NEO212 + Nivolumab Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis Recruiting USA 0
NCT06107413 Phase II ABBV-400 + Bevacizumab + Fluorouracil + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab Recruiting USA 4
NCT04014530 Phase Ib/II Pembrolizumab + PTC124 Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study (ATAPEMBRO) Recruiting NLD 0
NCT04906382 Phase I Carboplatin + Paclitaxel + Tislelizumab Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer Terminated USA 0
NCT05177133 Phase II Capecitabine + Oxaliplatin + Retifanlimab Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus) (AuspiCiOus) Recruiting NLD 0
NCT04282018 Phase Ib/II BGB-10188 + Zanubrutinib BGB-10188 + Tislelizumab BGB-10188 Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab Recruiting AUS 1
NCT05417386 Phase I Fluorouracil + Irinotecan + Leucovorin + NIS793 + Oxaliplatin Capecitabine + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin FOLFIRINOX + NIS793 in Pancreatic Cancer Recruiting USA 0
NCT05217446 Phase II Pembrolizumab Cetuximab + Encorafenib + Pembrolizumab A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer (SEAMARK) Recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 6
NCT03871959 Phase I Pembrolizumab + Xevinapant Pembrolizumab In Combination With Debio 1143 In Pancreatic and Colorectal Advanced/Metastatic Adenocarcinoma (CATRIPCA) Completed FRA 0
NCT04787042 Phase Ib/II Pembrolizumab + ST-067 ST-067 Obinutuzumab + ST-067 Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 Recruiting USA 0
NCT05118724 Phase II Atezolizumab Atezolizumab in Patients With MSI-h/MMR-D Stage III Colorectal Cancer Ineligible for Oxaliplatin (ANTONIO) Recruiting DEU 0
NCT05672524 Phase II Trastuzumab + Tucatinib A Study of Tucatinib and Trastuzumab in People With Rectal Cancer Recruiting USA 0
NCT06046274 Phase II GEN1046 + Pembrolizumab GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer Not yet recruiting USA | ITA | ESP | BEL 2
NCT05419817 Phase II Pembrolizumab + Sitravatinib Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System Withdrawn 0
NCT04935359 Phase III Gemcitabine + Nab-paclitaxel + NIS793 Gemcitabine + Nab-paclitaxel Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2 Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 17
NCT05272709 Phase Ib/II TT-702 TT-702 in Patients With Advanced Solid Tumours. (CURATE) Recruiting GBR 0
NCT02912572 Phase II Avelumab + Talazoparib Avelumab Avelumab + Axitinib Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer Active, not recruiting USA 0
NCT05000294 Phase Ib/II Atezolizumab + Tivozanib Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types Recruiting USA 0
NCT05308446 Phase II Cetuximab + Encorafenib Cetuximab + Encorafenib + Nivolumab Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation Recruiting USA 1
NCT05427487 Phase I IVX037 Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours Recruiting AUS 0
NCT05029882 Phase I ABBV-400 + Bevacizumab ABBV-400 Bevacizumab + Trifluridine-tipiracil hydrochloride Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab Recruiting USA | FRA | ESP | AUS 6
NCT04705818 Phase II Durvalumab + Tazemetostat Combining Epigenetic And Immune Therapy to Beat Cancer. (CAIRE) Recruiting FRA 0
NCT05603910 Phase I Lenvatinib + Pembrolizumab Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma Recruiting USA 0
NCT06278857 Phase II Dostarlimab-gxly SATELLITE Study (feaSibility sAfeTy Efficacy dostarLimab earLy-stage defIcient endomeTrial cancEr) (SATELLITE) Not yet recruiting AUS 0
NCT03803553 Phase III Binimetinib + Cetuximab + Encorafenib Nivolumab Fluorouracil + Irinotecan + Leucovorin Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer Recruiting USA 0
NCT04817826 Phase II Durvalumab + Tremelimumab TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC. (INFINITY) Recruiting ITA 0
NCT05199272 Phase Ib/II 23ME-00610 A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies Active, not recruiting USA | CAN 0
NCT04551521 Phase II Atezolizumab Atezolizumab + Ipatasertib Atezolizumab + Pertuzumab + Trastuzumab Atezolizumab + Cobimetinib Alectinib Atezolizumab + Cobimetinib + Vemurafenib CRAFT: The NCT-PMO-1602 Phase II Trial Recruiting DEU 0
NCT05854498 Phase II Bevacizumab + Liposomal irinotecan + Trifluridine-tipiracil hydrochloride Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer Recruiting USA 0
NCT06152523 Phase II MEDI5752 + Monalizumab Monalizumab and MEDI5752 in Patients With MSI and/or dMMR Metastatic Cancer (MONAMI) Not yet recruiting FRA 0
NCT06036836 Phase II Lenvatinib + Pembrolizumab Lenvatinib + MK-4280A MK-4280A Pembrolizumab Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) Recruiting USA | NLD | CAN | AUS 3
NCT05919264 Phase Ib/II FOG-001 FOG-001 in Locally Advanced or Metastatic Solid Tumors Recruiting USA 0
NCT03186326 Phase II Aflibercept + Fluorouracil + Irinotecan + Leucovorin Aflibercept + Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin + Panitumumab Cetuximab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Fluorouracil + Irinotecan + Leucovorin + Panitumumab Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin Avelumab Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer (SAMCO) Active, not recruiting FRA 0
NCT05077800 Phase II Elraglusib + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin + Losartan + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Elraglusib + Fluorouracil + Irinotecan + Leucovorin + Losartan + Oxaliplatin FOLFIRINOX + 9-Ing-41 + Losartan In Pancreatic Cancer Recruiting USA 0
NCT05263492 Phase II Lenvatinib + Pembrolizumab Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer Recruiting USA 0
NCT04895722 Phase II MK-4280A MK-7684A MK-1308A MK-4830 + Pembrolizumab Pembrolizumab Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008) Recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL 13
NCT05069935 Phase I Atezolizumab + FT538 Cetuximab + FT538 FT538 + Trastuzumab FT538 + Pembrolizumab FT538 + Nivolumab Avelumab + FT538 Cyclophosphamide + Fludarabine FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors Terminated USA 0
NCT05984602 Phase I Canakinumab + Gemcitabine + Nab-paclitaxel + Tislelizumab A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer Recruiting USA 0
NCT03212404 Phase I Cosibelimab Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers Recruiting NZL | FRA | ESP | AUS 5
NCT05710406 Phase II Cetuximab + Encorafenib Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer Recruiting USA 0
NCT06065462 Phase Ib/II Dostarlimab-gxly + LB-100 Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100 Recruiting USA 0
NCT05112601 Phase II Ipilimumab + Nivolumab Nivolumab Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma Recruiting USA 0
NCT04729959 Phase II Atezolizumab + Tocilizumab Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma Recruiting USA 0
NCT05672095 Phase Ib/II Niraparib Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer Not yet recruiting USA 0
NCT04450901 Phase I YBL-006 Dose Escalation/Dose Expansion Study of YBL-006 in Patients With Advanced Solid Tumors Active, not recruiting AUS 2
NCT05425940 Phase III Atezolizumab + XL092 Regorafenib Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer (STELLAR-303) Recruiting USA | NZL | GBR | FRA | ESP | DEU | BEL | AUS 8
NCT05723562 Phase II Dostarlimab-gxly A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer (AZUR-1) Recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN 2
NCT04952753 Phase II Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + NIS793 Bevacizumab + Fluorouracil + Leucovorin + NIS793 + Oxaliplatin Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC (daNIS-3) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 8
NCT05200559 Phase Ib/II E7777 + Pembrolizumab T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors Recruiting USA 0
NCT04837196 Phase Ib/II ASP7517 + Pembrolizumab ASP7517 Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen Active, not recruiting USA 0
NCT04991948 Phase I Fluorouracil + Leucovorin + NKR-2 cells + Oxaliplatin + Pembrolizumab Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer Recruiting USA | BEL 0
NCT06034860 Phase I MT-8421 + Nivolumab MT-8421 Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types Recruiting USA 0
NCT05005728 Phase II XmAb20717 Olaparib + XmAb20717 Cabazitaxel + Carboplatin + XmAb20717 XmAb20717 Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer Recruiting USA 0
NCT05684965 Phase I XTX301 XTX301 in Patients With Advanced Solid Tumors Recruiting USA 0
NCT04006262 Phase II Ipilimumab + Nivolumab Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma. (NEONIPIGA) Recruiting FRA 0
NCT04729322 Phase I Fecal microbiota + Nivolumab Fecal microbiota + Pembrolizumab Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders Active, not recruiting USA 0
NCT05870800 Phase II Atezolizumab + Capecitabine + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin Capecitabine + Oxaliplatin Neoadjuvant Chemoimmunotherapy for Resectable Non-Metastatic Proficient Mismatch Repair (PMMR) Colon Cancer Not yet recruiting USA 0